A Phase 4 interventional study of 3% Benzoyl Peroxide and 3% Benzoyl Peroxide Placebo in Skin Diseases, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 12 Years to 45 Years. Per ClinicalTrials.gov, last updated 2015-05-18.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 202 studies in Skin Diseases with a site in United States — 32 open to participants now, 49 under way, 9 of them phase 3. Skin Diseases · United States.
Among the 202 studies in Skin Diseases with a site in United States, this one is the 88th largest by enrollment of the 172 interventional ones that give a count, is one of 3 that started in 2014, is one of 8 in phase 4, and was the 57th registered.
496 studies on the registry are indexed under Skin Diseases; 78 are open to participants now.
Browse Skin Diseases studies →32 of the 202 studies in Skin Diseases with a site in United States are open now. Recruiting first, the newest first:
IAS Skin Care · Sites in United States
Ages 25–65 · Women only · Healthy volunteers
WiQo S.p.A. · Sites in United States
Ages 18+ · Healthy volunteers
Spyre Therapeutics, Inc. · Sites in United States, Canada
Ages 18–75
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
Pfizer · Sites in United States, Canada, Japan
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 55 Skin Diseases studies recruiting now, 27 (49%) set no upper age limit and 18 (33%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.
This study: 12 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
202 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 69 · Phase 3 46 · Phase 4 8
First in 1978; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 70 across 375 interventional studies indexed under Skin Diseases.
Median enrollment 99 across the 172 interventional studies, 298 across the 28 observational. Of the 142 that completed or were terminated, 90 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
139 of 202 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 8 studies filed under Skin Diseases — fewer than ten, so there is no comparison to draw.
19 of the studies in Skin Diseases with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07144345Phase 3Sun Pharmaceutical Industries, Inc.Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp | 2027-01 |
| NCT07144852Phase 3Sun Pharmaceutical Industries, Inc.Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities | 2027-01 |
| NCT07717346Krystal Biotech, Inc.A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease | 2026-11 |
| NCT06674980C5 BiomedicalClinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs | 2026-11-22 |
| NCT07866131WiQo S.p.A.Observational Assessment of Skin Appearance Changes During PRX S Cosmetic Treatment in Participants With Acne-Prone Skin | 2026-12 |
Add all 19 to your calendar (.ics) → With an account.
Among the 202 studies in Skin Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
5 Day study to assess how quickly a topical acne product begins to work.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Sexually active females of participating in the study must agree to use a medically acceptable method of while receiving protocol-assigned product. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant; including perimenopausal women who are less than 2 years from their last menses. Acceptable contraceptive methods include the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
Drug: 3% Benzoyl Peroxide
The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
Drug: 3% Benzoyl Peroxide Placebo
A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
Drug: Neutrogena Rapid Clear®
Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
To Assess the Percentage Change in Acne Lesion Swelling (Height) of the Target Lesion for 3% Benzoyl Peroxide (BPO) Gel Test Product Relative to the Vehicle Gel After 4 Once-daily Applications.
The Investigator assessed and score each target lesion's swelling (elevation), elevation scores were the actual dimensions, i.e. the value in millimeters at the lesion's highest points. Percent change in height of all three target lesions were calculated and averaged for each participant. The average lesion height at baseline was calculated for each participant. An analysis of covariance (ANCOVA) was performed with average percentage change in target lesion height as the response variable, treatment group (3% BPO or vehicle) as a main effect, and average baseline target lesion height as a covariate. A greater reduction in the percentage change in height of the target lesions indicated a better outcome measure
Time frame: Baseline to Day 4
To Assess the Percentage Change in Acne Lesion Swelling (Height) for the 3% Benzoyl Peroxide Gel Test Product and Positive Control Relative to the Vehicle Gel.
The Investigator assessed and score each target lesion's swelling (elevation), elevation scores were the actual dimensions, i.e. the value in millimeters at the lesion's highest points. Percent change in height of all three target lesions were calculated and averaged for each participant. The average lesion height at baseline was calculated for each participant
Time frame: Baseline to 2 hours, 4 hours, Day 1, Day 2 and Day 4
To Assess the Change in Acne Lesion Redness (Erythema) for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel.
The investigator assessed the erythema of the target lesion according to the following scale and tabulated the responses: 0=none, 1=minimal, 2=mild, 3=-moderate, 4=severe.
Time frame: Baseline to 2 hours, 4 hours, Day 1, Day 2, and Day 4
To Assess the Percentage Change in Acne Lesion Diameter (Size) for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel.
The Investigator assessed and score each target lesion's diameter (size). Diameter scores were the actual dimensions, i.e. the value in millimeters at the lesion's widest or highest points.
Time frame: Baseline to 2 hours, 4 hours, Day 1, Day 2, and Day 4
To Assess the Change in Facial Skin Clarity for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel
The Skin clarity was measured using the following scale; 0 Very Clear; 1 Clear; 2 Dull; 3 Very Dull; 4 Unclear. The responses were then tabulated
Time frame: Baseline to 2 hours, 4 hours, Day 1, Day 2, and Day 4
To Assess the Change in Perceptions of the Overall Appearance of Their Skin for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel
The participants were asked to rate the overall appearance of their facial skin as; 1= Very Dissatisfied; 2= Slightly Dissatisfied; 3= Neither Satisfied nor Dissatisfied; 4= Slightly Satisfied; 5= Very Satisfied. The responses were then tabulated.
Time frame: Baseline to 2 hours, 4 hours, Day 1, Day 2, and Day 4
Participants were recruited at a clinical site in USA
| Milestone | Test Product | Vehicle Gel | Positive Control |
|---|---|---|---|
| Started | 30 | 30 | 30 |
| Completed | 30 | 30 | 30 |
| Not completed | 0 | 0 | 0 |
The Investigator assessed and score each target lesion's swelling (elevation), elevation scores were the actual dimensions, i.e. the value in millimeters at the lesion's highest points. Percent change in height of all three target lesions were calculated and averaged for each participant. The average lesion height at baseline was calculated for each participant. An analysis of covariance (ANCOVA) was performed with average percentage change in target lesion height as the response variable, treatment group (3% BPO or vehicle) as a main effect, and average baseline target lesion height as a covariate. A greater reduction in the percentage change in height of the target lesions indicated a better outcome measure
| Percentage change | Test Product | Vehicle Gel | Positive Control |
|---|---|---|---|
| To Assess the Percentage Change in Acne Lesion Swelling (Height) of the Target Lesion for 3% Benzoyl Peroxide (BPO) Gel Test Product Relative to the Vehicle Gel After 4 Once-daily Applications. | -57.42 ± 6.229 | -47.89 ± 6.237 | -53.07 ± 6.233 |
The Investigator assessed and score each target lesion's swelling (elevation), elevation scores were the actual dimensions, i.e. the value in millimeters at the lesion's highest points. Percent change in height of all three target lesions were calculated and averaged for each participant. The average lesion height at baseline was calculated for each participant
| Percentage change | Test Product | Vehicle Gel | Positive Control |
|---|---|---|---|
| From baseline to hour 2 | -3.24 ± 8.726 | -4.65 ± 10.558 | -4.57 ± 10.754 |
| From baseline to hour 4 | -6.02 ± 9.172 | -7.01 ± 11.525 | -5.94 ± 11.774 |
| From baseline to day 1 | -21.42 ± 25.578 | -22.07 ± 19.688 | -20.22 ± 25.711 |
| From baseline to day 2 | -40.30 ± 34.011 | -37.03 ± 28.968 | -42.94 ± 31.121 |
| From baseline to day 4 | -57.22 ± 36.372 | -48.60 ± 34.585 | -52.57 ± 33.580 |
The investigator assessed the erythema of the target lesion according to the following scale and tabulated the responses: 0=none, 1=minimal, 2=mild, 3=-moderate, 4=severe.
| Units on a scale | Test Product | Vehicle Gel | Positive Control |
|---|---|---|---|
| Change from baseline to hour 2 | -0.04 ± 0.190 | -0.02 ± 0.122 | -0.03 ± 0.221 |
| Change from baseline to hour 4 | -0.12 ± 0.283 | -0.06 ± 0.304 | -0.10 ± 0.279 |
| Change from baseline to day 1 | -0.62 ± 0.811 | -0.56 ± 0.639 | -0.73 ± 0.851 |
| Change from baseline to day 2 | -1.26 ± 1.225 | -1.02 ± 0.967 | -1.36 ± 1.168 |
| Change from baseline to day 4 | -1.83 ± 1.228 | -1.39 ± 1.247 | -1.84 ± 1.303 |
The Investigator assessed and score each target lesion's diameter (size). Diameter scores were the actual dimensions, i.e. the value in millimeters at the lesion's widest or highest points.
| Percentage change | Test Product | Vehicle Gel | Positive Control |
|---|---|---|---|
| From baseline to hour 2 | -0.46 ± 10.920 | -1.33 ± 7.274 | -0.33 ± 7.112 |
| From baseline to hour 4 | -0.74 ± 9.397 | -0.22 ± 10.666 | -0.63 ± 9.244 |
| From baseline to day 1 | -12.46 ± 27.993 | -12.83 ± 20.836 | -11.93 ± 22.049 |
| From baseline to day 2 | -30.98 ± 38.935 | -29.81 ± 36.983 | -37.83 ± 32.315 |
| From baseline to day 4 | -52.56 ± 39.058 | -38.78 ± 44.7000 | -44.78 ± 35.933 |
The Skin clarity was measured using the following scale; 0 Very Clear; 1 Clear; 2 Dull; 3 Very Dull; 4 Unclear. The responses were then tabulated
| Units on a scale | Test Product | Vehicle Gel | Positive Control |
|---|---|---|---|
| Baseline to hour 2 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Baseline to hour 4 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Baseline to day 1 | -0.2 ± 0.43 | -0.2 ± 0.38 | -0.3 ± 0.48 |
| Baseline to day 2 | -0.8 ± 0.81 | -0.5 ± 0.51 | -0.7 ± 0.84 |
| Baseline to day 4 | -1.2 ± 0.90 | -0.7 ± 0.79 | -1.0 ± 0.98 |
The participants were asked to rate the overall appearance of their facial skin as; 1= Very Dissatisfied; 2= Slightly Dissatisfied; 3= Neither Satisfied nor Dissatisfied; 4= Slightly Satisfied; 5= Very Satisfied. The responses were then tabulated.
| Units on a scale | Test Product | Vehicle Gel | Positive Control |
|---|---|---|---|
| Change from baseline to hour 2 | 0.3 ± 0.84 | 0.1 ± 0.82 | 0.3 ± 0.71 |
| Change from baseline to hour 4 | 0.4 ± 0.93 | 0.3 ± 0.99 | 0.4 ± 1.07 |
| Change from baseline to day 1 | 0.3 ± 0.92 | 0.3 ± 1.03 | 0.4 ± 1.13 |
| Change from baseline to day 2 | 0.5 ± 1.14 | 0.6 ± 1.03 | 0.7 ± 1.24 |
| Change from baseline to day 4 | 0.9 ± 1.03 | 0.8 ± 1.30 | 0.8 ± 1.32 |
Collected over 5 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test Product | — | 0/30 (0%) | 0/30 (0%) |
| Vehicle Gel | — | 0/30 (0%) | 0/30 (0%) |
| Positive Control | — | 0/30 (0%) | 0/30 (0%) |
| Age, Continuous(Years) | Test Product | Vehicle Gel | Positive Control | Total |
|---|---|---|---|---|
| Mean | 22.1 ± 9.90 | 20.3 ± 7.47 | 17.8 ± 6.22 | 20.1 ± 8.11 |
| Sex: Female, Male(Participants) | Test Product | Vehicle Gel | Positive Control | Total |
|---|---|---|---|---|
| Female | 18 ± 60.0 | 17 ± 56.7 | 12 ± 40.0 | 47 |
| Male | 12 ± 40.0 | 13 ± 43.3 | 18 ± 60.0 | 43 |
The record gives a start of Feb 2014, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in May 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benzoyl Peroxide